VENTX is a homeobox transcription factor and member of the NK-like (NKL) subclass that functions as a key regulator of hematopoietic cell differentiation and immune cell development 1. As a DNA-binding transcriptional factor, VENTX promotes myeloid differentiation by activating myeloid-associated genes while suppressing lymphoid development genes 2. VENTX plays pivotal roles in terminal differentiation of both dendritic cells and macrophages from monocytic precursors, with expression regulated by transcription factors including CEBPB, GATA2, and SPI1, and by CSF-, NOTCH-, and TNFα signaling pathways 345. In normal hematopoiesis, VENTX suppression enhances expansion of hematopoietic stem/multipotent progenitor cells through regulation of cell cycle regulators 6. Clinically, VENTX is aberrantly overexpressed in acute myeloid leukemia (AML), particularly in leukemic CD34+ cells, where it promotes myeloid progression and inhibits AML cell line proliferation when knocked down 2. Additionally, VENTX expression is reduced in tumor-associated macrophages and restoration promotes anti-tumor M1 polarization, suggesting therapeutic potential in cancer immunotherapy 7. VENTX is also essential for human pluripotent stem cell fitness 8, and dysregulation correlates with autoimmune disease pathogenesis 5.